Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UNG | P13051 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SCN2B | O60939 | 4/20 | 0.41 |
| ▸ | SCN1A | P35498 | 4/20 | 0.41 |
| ▸ | SCN1B | Q07699 | 4/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | NAT1 | P18440 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652743 | 0.89 | HPGD (0.51) | UNGHDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL12374675 | 0.86 | HDAC3 (0.44) | HDAC3HDAC1SCN9ASCN3ASCN2B | |
| SCHEMBL27210087 | 0.81 | HDAC1 (0.65) | UNGHDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL62779 | 0.80 | UNG (0.61) | UNGHDAC3HDAC1NAT1HDAC8 | |
| SCHEMBL29957694 | 0.80 | UNG (0.61) | UNGHDAC3HDAC1NAT1HDAC8 | |
| SCHEMBL2159159 | 0.78 | PKM (0.51) | HDAC1SCN9ASCN3ASCN2BSCN1A | |
| SCHEMBL13331743 | 0.78 | KDM4E (0.65) | SCN9ASCN3AHDAC8HDAC6ALDH1A1 | |
| SCHEMBL280256 | 0.78 | HDAC8 (0.68) | SCN9ASCN2BSCN1ASCN1BHDAC8 | |
| SCHEMBL27601199 | 0.78 | UNG (0.44) | UNGHDAC3HDAC1SMN1; SMN2 | |
| SCHEMBL7990892 | 0.77 | HDAC1 (0.66) | HDAC1SCN9ASCN2BSCN1ASCN1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1671961-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1671948-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | COL2A1, COL1A1, COL14A1 | UNG 3128/4885HDAC3 1688/4885HDAC1 1097/4885 |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | NPC1, CES2, CYP51A1 | UNG 4052/4885HDAC3 189/4885HDAC1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.